7 best EDC software platforms for CROs in 2026

Your data management team quoted the sponsor a study go-live in six weeks. Now you're three months in, waiting on a vendor programmer to finish the database build, and the sponsor is asking questions you don't have good answers to. That gap -- between what you promised and what your electronic data capture (EDC) platform actually delivers -- is a margin problem, a relationship problem, and a competitive problem rolled into one. Viedoc's EDC software is built to close that gap: study builds typically completed in 2--4 weeks using a no-code Designer your team configures in-house, backed by 24/7 support across 7,000+ completed studies in 75+ countries. This comparison evaluates seven leading EDC platforms for contract research organizations (CROs) across study build speed, no-code configuration capability, compliance credentials, support model, and total cost of ownership.

For small-to-mid-size (SMID) CROs managing multiple concurrent studies across different sponsors, phases, and therapeutic areas, EDC platform choice is a direct driver of operational margin. Build timelines, amendment velocity, training overhead, and per-seat pricing models all compound across a portfolio of 10, 20, or 50 active studies.

Enterprise EDC platforms weren't designed for your operating model. They were built for big pharma procurement teams with multi-year implementation budgets and dedicated programming teams to manage every study change. When you're building studies independently for growth-stage sponsors, that architecture adds cost and drag you can't absorb.

Best EDC software for CROs: quick comparison

These seven EDC platforms represent the most commonly evaluated options for SMID CROs, reviewed across study build speed, configuration model, compliance coverage, and support infrastructure.

1. Viedoc

Viedoc's EDC software is designed for CROs that need to build, launch, and amend studies independently -- without waiting on a vendor programming queue. Across 7,000+ completed studies in 75+ countries, supporting 1.6 million trial participants at 30,000+ sites, it's one of the most widely deployed EDC platforms in the SMID clinical research market.

For CROs, two capabilities define the operational advantage. Viedoc Designer is a no-code study configuration tool that lets your certified data managers build studies, configure logic, and execute mid-study amendments in-house -- no programmer required and no vendor dependency for routine changes. Viedoc's CRO Partner Program adds preferred-vendor positioning with sponsors, tiered partnership benefits, and access to a certified CRO network that creates repeat study volume.

The platform's compliance posture covers the full regulatory stack your CRO clients will ask about: ISO 27001 and SOC 2 Type II certified; 21 CFR Part 11, ICH GCP, EU Annex 11, GDPR, and HIPAA compliant; hosted on Microsoft Azure with 99.99% uptime. The Viedoc Inspection Readiness Packet (VIRP) is structured audit-readiness documentation available to all customers at no additional cost, covering EMA, FDA, and PMDA inspection requirements. Viedoc's 24/7 customer support operates across global offices, not a ticket-only system.

"Viedoc makes building a study easy and fun. It doesn't require extensive coding knowledge; it's quick to get in and start working." — Cindy H., Project Support Associate

Verified proof points:

• Study scale: 7,000+ studies run on Viedoc across 75+ countries
• User base: 140,000+ users globally; 30,000+ sites
• Build speed: Study builds typically completed in 2--4 weeks; mid-study amendments completed in days
• Uptime: 99.99% platform uptime; hosted on Microsoft Azure
• Pricing: Unlimited user seats; no per-user fees; transparent, study-based licensing
• Compliance: 21 CFR Part 11, ICH GCP, GDPR, EU Annex 11, HIPAA; ISO 27001 and SOC 2 Type II certified
• Inspection readiness: Viedoc Inspection Readiness Packet (VIRP) available to all customers at no additional cost
• Support: 24/7 support across global offices; not ticket-only

Launch, manage, and monitor clinical trials faster with intuitive EDC clinical trial software that keeps you compliant and audit ready.

2. Medidata

Medidata offers Medidata Rave EDC, the dominant enterprise EDC platform in the global clinical research market, used across large pharma, global biotech, and late-phase sponsors. Owned by Dassault Systèmes since 2019, Rave integrates with Medidata's broader platform including CTMS, eCOA, and safety tools. Study builds require trained programmers for configuration, and build timelines for new studies typically extend to up to 90 days, with amendments following a similar dependency on vendor-side resources. Medidata carries strong credibility with FDA-facing regulatory teams and is regarded as the category standard for complex global Phase III trials. Per-seat and per-study pricing compounds at scale in ways that can make it a poor economic fit for SMID CROs running multiple concurrent smaller studies.

3. Veeva Vault EDC

Veeva offers Veeva Vault EDC as part of its broader Vault Clinical suite, targeting sponsors seeking integrated electronic trial master file (eTMF), CTMS, and EDC within a single cloud platform. The platform uses a modern cloud architecture with zero-downtime updates and is positioned primarily at mid-to-large pharma sponsors already using Vault for other modules. Vault EDC carries 21 CFR Part 11, GDPR, and ISO certifications and is a credible modern challenger to Medidata for sponsors transitioning off legacy systems. For CROs not embedded in the Vault ecosystem, the suite-first architecture can mean buying more platform than a standalone EDC requirement demands, and CRO adoption of Vault EDC remains lower than sponsor adoption.

4. Castor EDC

Castor EDC is a no-code, API-first EDC platform with a cloud-native architecture and self-service study configuration capability. The platform is used across academic research, digital health, and regulated commercial trials, and offers a free tier for academic studies alongside paid commercial licensing. Castor integrates eConsent and ePRO within its platform and has built visible presence in AI-driven EDC comparisons. Professional services infrastructure and 24/7 global support are more limited than larger vendors, which is a consideration for CROs running time-sensitive multi-site studies. Castor's module depth -- lacking native RTSM, eTMF, and medical coding -- means CROs needing a fuller eClinical suite may need to manage additional vendor relationships alongside it.

5. Medrio

Medrio offers a user-friendly EDC platform with particular strength in Phase I clinical pharmacology studies and medical device trials. Available in 100+ countries, Medrio supports offline data capture -- a capability relevant for site environments with limited connectivity. The platform has established partnerships with contract research organizations and clinical technology vendors including providers covering CTMS, eTMF, and risk-based quality management. Medrio has historically been positioned at CROs and smaller biotech and pharma sponsors running studies of lower-to-moderate protocol complexity, and lacks the full eClinical suite depth of larger vendors.

6. Oracle InForm

Oracle Health offers Oracle InForm as part of its Health Sciences platform, a legacy enterprise EDC historically strong in global, multi-site Phase III trials. InForm has deep integrations across Oracle's broader health sciences product portfolio including safety and randomization tools, and has an established global reach in regulated commercial research. The platform's user interface architecture is older than modern cloud-native alternatives, and it carries a perception of lower agility for mid-study amendments relative to newer platforms. CROs considering InForm should evaluate the total configuration and programming overhead alongside the platform's integration ecosystem.

What to look for in EDC software for SMID CROs

Study build and amendment velocity

For CROs, study build speed isn't a nice-to-have -- it's a direct driver of billing milestone timing, sponsor satisfaction, and competitive win rates on future work. The industry benchmark for legacy enterprise EDC platforms sits at up to 90 days per build, a timeline driven primarily by programmer-dependent configuration models. Modern no-code platforms have compressed this significantly, and the difference shows up directly in your delivery margin.

Best-in-class for SMID CROs means going from a signed work order to study go-live in 2--4 weeks for standard studies, with mid-study amendments executed in days rather than weeks. Platforms that require vendor-side programmer involvement for every amendment create a dependency that compounds across your portfolio -- each open change request stacks against every other active study you're running.

Scrutinize amendment turnaround times as carefully as initial build timelines. A fast go-live means nothing if a protocol change at week 12 takes 45 days to implement and triggers a cascade of sponsor escalations.

No-code versus programmer-dependent configuration

Every time your data management team submits a request to a vendor programmer, you're paying for it -- in billable hours, in calendar time, and in the unpredictability that creates for sponsor delivery commitments. No-code study configuration means your certified data managers own the build and the amendment process end-to-end, without external dependency.

What good looks like: a visual study designer that lets certified in-house staff configure electronic case report forms (eCRFs), edit checks, and workflow logic without requiring code or scripting knowledge. Viedoc's EDC software uses a no-code Designer interface with Certified Designer Training that enables your team to self-build from day one.

A programmer-dependent platform is not merely a cost issue -- it's a capacity constraint. When your vendor's programming team is backlogged, your study sits waiting regardless of the urgency.

Compliance coverage and inspection readiness documentation

Your QA and computer system validation (CSV) lead will evaluate EDC platforms on this criterion first, and they have veto authority over the final decision. FDA 21 CFR Part 11, ICH GCP, EU Annex 11, and GDPR are baseline requirements. ISO 27001 and SOC 2 Type II certification demonstrate that information security controls have been independently audited -- a requirement increasingly imposed by enterprise sponsor procurement teams.

What separates good from great is inspection readiness documentation. Pre-built validation packs, structured audit trail exports, and clear change-control documentation reduce the QA burden on your team and accelerate CSV sign-off when onboarding new studies. Platforms that require you to build this documentation from scratch add weeks to your internal validation cycle.

Confirm HIPAA attestation for any US sponsor studies involving protected health information (PHI). For multi-regional studies, verify that the platform's data residency and sovereignty posture aligns with GDPR requirements -- especially for European Union site data.

Support model and escalation pathways

24/7 support availability is a non-negotiable for CROs running studies across time zones. What matters beyond availability is how issues are actually resolved: ticket-only systems are inadequate for site activation problems, database lock escalations, or mid-study amendment dependencies that carry sponsor milestone implications.

Best-in-class means named account management for higher-volume CROs, direct escalation pathways outside of standard ticket queues, and documented service level agreements (SLAs) for different issue categories. Response time during a database lock or inspection query can have regulatory consequences -- your support SLA needs to reflect that reality.

Ask vendors for mean time to resolution data across their CRO customer base, not just first-response times. The difference between a two-hour first response and a 48-hour full resolution matters considerably when sites are waiting.

Pricing model and total cost of ownership

Per-seat pricing penalizes you for scale. As your study team grows -- as you add monitors, investigators, and site staff to active studies -- per-seat fees compound. A pricing model built on unlimited user seats removes that structural cost exposure and lets you bid confidently on studies of varying site and headcount complexity.

Total cost of ownership (TCO) for EDC extends well beyond license fees. Include internal programmer hours for configuration, IT security review and validation overhead, training and onboarding time per new study, and the cost of amendments. A lower headline license fee on a programmer-dependent platform can easily be outweighed by internal labor costs that a no-code alternative eliminates.

Scrutinize what is included as standard versus what triggers additional fees. Amendment support, report configuration, training materials, and validation documentation are all areas where some vendors invoice separately.

How to choose the right EDC software for SMID CROs

Step 1: Define your study portfolio profile

Before evaluating platforms, map the actual range of your study work: phases, therapeutic areas, typical protocol complexity, average number of concurrent active studies, and geographic distribution. A CRO running mostly Phase I first-in-human studies for biotech sponsors in a single country has different requirements than one managing multinational Phase II oncology trials for four sponsors simultaneously. Your platform needs to handle both your current portfolio and your projected growth.

Step 2: Assess your team's in-house configuration capability

Whether your data management team can build and amend studies independently -- or whether you'll depend on vendor programming for every change -- is the single most consequential operational question in EDC platform selection. Map your current staffing: do you have certified designers or data managers with configuration experience? The answer shapes which platform type makes commercial sense for your operating model.

Step 3: Scrutinize sponsor requirements for the next 18 months

Your sponsors' regulatory and compliance requirements define the minimum bar your EDC platform must meet. For US sponsors, FDA 21 CFR Part 11 and HIPAA attestation are table stakes. For European sponsors, EU Annex 11 and GDPR data residency matter. For sponsors with quality management system (QMS) requirements, ISO 27001 and SOC 2 certification may be contractually required. Shortlist only platforms that clear your most demanding sponsor's compliance requirements -- not your average sponsor's.

Step 4: Evaluate the amendment workflow, not just the go-live timeline

Most vendors lead with initial build speed during demos. What separates platforms at six and twelve months into a study is amendment velocity: how quickly can your team respond to a protocol change, implement new edit checks, or add a CRF form without raising a vendor ticket? Require vendors to demonstrate their amendment workflow live during the evaluation -- including who performs the change, how long it takes, and what the change-control documentation trail looks like.

Step 5: Choose the platform that matches your operational model, then verify it

If you need in-house configuration capability, verified compliance credentials, 24/7 support, and a pricing model that doesn't penalize you for growing headcount, Viedoc's EDC software is built for that operating model. You can book a demo to see the no-code Designer workflow and study build process in the context of your own trial portfolio, or request a proposal to see how the pricing model maps to your current study volume.

Frequently asked questions

What is the best EDC software for SMID CROs?

Viedoc's EDC software is the leading choice for SMID CROs, offering study builds typically completed in 2--4 weeks, a no-code Designer that enables in-house certified data managers to configure and amend studies without vendor programming support, and a transparent pricing model with unlimited user seats. Viedoc is used across 7,000+ completed studies in 75+ countries and carries ISO 27001, SOC 2 Type II, 21 CFR Part 11, and GDPR compliance credentials. Medidata Rave EDC is the category standard for large pharma and complex Phase III trials, though it operates on significantly longer build timelines and a programmer-dependent configuration model. Castor EDC is a strong option for CROs working on academic-adjacent or early digital health studies where its no-code interface and free tier are competitive advantages.

What should I look for when choosing an EDC platform as a CRO?

Prioritize study build and amendment speed, the ability to configure studies in-house without vendor programmer dependency, compliance coverage that meets your most demanding sponsor's requirements, and a support model that offers 24/7 access with direct escalation pathways -- not just a ticket queue. Beyond the headline license fee, evaluate total cost of ownership across internal labor, training, validation documentation, and amendment support. Per-user pricing models can create significant cost exposure as your study team and site headcounts grow across an active portfolio.

How long does it take to build and deploy a clinical study on a modern EDC platform?

On modern no-code EDC platforms, study go-live timelines have compressed significantly compared to legacy enterprise platforms. Viedoc's EDC software delivers study builds typically completed in 2--4 weeks for self-service customers. Legacy programmer-dependent platforms can operate on timelines of up to 90 days per build, driven by vendor programming queue dependency. Mid-study amendment speed matters as much as initial build time -- modern platforms that allow in-house amendment execution can turn around protocol changes in days rather than weeks.

What EDC features matter most to CROs managing multiple concurrent studies?

Portfolio-scale CROs need template reuse and standardized form libraries to reduce configuration time per new study, amendment workflows that don't require vendor involvement for routine changes, real-time data dashboards that give your monitors and clinical research associates (CRAs) visibility across all active studies simultaneously, and user management that doesn't create per-seat cost exposure as team sizes fluctuate. Training governance is also critical -- platforms that require minimal retraining for new staff and offer structured certification pathways reduce internal onboarding overhead significantly across a high-volume portfolio.

What is the Viedoc Inspection Readiness Packet (VIRP)?

The Viedoc Inspection Readiness Packet (VIRP) is a structured set of audit-readiness documentation available to all Viedoc customers at no additional cost, designed to help clinical trial teams meet the documentation expectations of major regulatory bodies including the FDA, EMA, and PMDA. VIRP covers system validation documentation, audit trail guidance, data integrity requirements, and CSV support materials aligned to FDA 21 CFR Part 11, EMA computerized systems guidance, and PMDA expectations. For CRO QA/CSV teams, VIRP reduces the time required to prepare and validate EDC systems for sponsor and regulatory audits. It is accessible directly within Viedoc Admin once a study is live.

What is the difference between per-seat and per-study EDC licensing for CROs?

Per-seat licensing charges for each user with platform access -- investigators, monitors, data managers, and site staff -- which creates cost exposure that scales unpredictably as study teams grow and headcounts fluctuate across a portfolio. Per-study licensing ties the cost to the number of active studies rather than the number of users, which is structurally better aligned to how CROs generate revenue. Unlimited user seat models, such as the one Viedoc's EDC software uses, remove headcount cost risk entirely and let you scale site and team access without incremental license fees. When evaluating pricing models, ask vendors to model both approaches across your projected study volume and average site headcount for the next 12 months.

Making the right EDC choice for SMID CROs

The eClinical software market is estimated at over $11 billion globally in 2025 and growing at approximately 14% annually, which means the range of platforms available to CROs has expanded considerably -- from legacy enterprise incumbents to modern no-code cloud-native alternatives. Across the platforms reviewed here, the core architectural divide is between programmer-dependent enterprise systems built for big pharma procurement cycles and self-service modular platforms designed for organizations that need to operate independently.

Matching platform to operating model depends on factors specific to your CRO: study phase complexity, team configuration capability, sponsor compliance requirements, geographic footprint, and whether you're optimizing for a high-volume portfolio of smaller studies or a lower volume of complex multi-regional trials. US CROs typically weight speed and margin efficiency most heavily; EMEA and APAC CROs often have stronger compliance credential and data residency requirements that narrow the shortlist further. Getting this match right at the outset is meaningful -- switching EDC platforms mid-portfolio triggers revalidation cycles, sponsor notification obligations, and staff retraining that carry real operational cost.

EDC platform decisions compound over time. A build-time advantage of four to six weeks per study, replicated across 20 active studies per year, represents a material difference in billable milestone timing and sponsor relationship health.

Why Viedoc is the best EDC software for SMID CROs

If your data management team is spending time waiting on vendor programming queues instead of configuring and launching studies independently, you're carrying an operational cost that shows up in every delivery commitment you make to sponsors. Viedoc's EDC software removes that dependency: a no-code Designer your certified data managers own end-to-end, with study builds typically completed in 2--4 weeks and amendment turnarounds in days rather than weeks.

The platform is trusted across 7,000+ completed studies in 75+ countries, with 140,000+ users and 1.6 million trial participants at 30,000+ sites. Compliance credentials cover the full stack your sponsors will ask for: ISO 27001 and SOC 2 Type II certified; FDA 21 CFR Part 11, ICH GCP, EU Annex 11, GDPR, and HIPAA compliant; with VIRP audit-readiness documentation included at no additional cost. Unlimited user seats mean your pricing doesn't inflate as your team and site headcounts grow across an active portfolio.

Viedoc's CRO Partner Program adds preferred-vendor positioning with sponsors and tiered partnership benefits that create repeat study volume -- built specifically for CROs, not retrofitted from a pharma sponsor model. Founded in 2003 and deployed across 20+ years of regulated clinical research, it's a platform with the track record your QA/CSV team needs to see.

If you're ready to see the study build workflow in the context of your own trial portfolio, book a demo or request a proposal and our team will walk you through build speed, compliance credentials, and module depth for your specific operating model.